2022 Biggest Medtech Losers Welcome a Fresh Year

From major lawsuits and environmental controversy to recalls and botched M&A, these companies say good riddance to 2022.

Katie Hobbins, Managing Editor

January 9, 2023

7 Slides
thumbs down (Marina Demeshko) (1).jpg

2022 is done. Finished. Kaput.

And these companies are saying good riddance.

However, before they get to start the year anew, lets take a look back at the biggest lawsuits, shortages, recalls, and other controversies that plagued 2022’s biggest losers.

About the Author(s)

Katie Hobbins

Katie Hobbins

Managing Editor, MD+DI

Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].

See more from Katie Hobbins
Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like

Editors' Choice

M&A
A New Vision for Pixium’s Retinal Implants
Science Corporation to Acquire Pixium's Retinal Implants

Apr 26, 2024

FDA approved Boston Scientific's Farapulse system in January for pulsed field ablation treatment of atrial fibrillation.
Cardiovascular
Boston Scientific's Farapulse Is a Showstopper
Boston Scientific's Farapulse Is a Showstopper

Apr 25, 2024

Product Development
Proven Insights for Efficient Medical Device Design & Development
Practical Insights for Medical Device Design & Development

Apr 25, 2024

Recent Headlines